Atorvastatina NORMON 40 mg comprimidos recubiertos con película EFG

DRUG2 trials

Sponsors

Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz, Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Conditions

Patients at risk of cardiovascular disease susceptible of receiving high or moderate-intensity doses of statins.Spontaneous lobar ICH

Phase 3

Use of statins in patients with intracerebral hemorrhage

Not yet recruitingCTIS2024-511465-11-00

Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant PauSpontaneous lobar ICH

Target: 180Updated: 2025-05-12

Phase 4

A multicentre controlled, randomised, single-blind adaptive phase IV protocol to evaluate efficacy, safety and cost-efficacy of pre-emptive genotyping strategy in a population at risk of cardiovascular disease susceptible of receiving high or moderate-intensity doses of statins

RecruitingCTIS2023-509418-12-00

Fundacion Para La Investigacion Biomedica Del Hospital Universitario La PazPatients at risk of cardiovascular disease susceptible of receiving high or moderate-intensity doses of statins.

Start: 2024-06-05Target: 216Updated: 2025-11-13

Related Papers

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial

BMJ Open2024-11-01